# A Study of IV HBI-3000 for the Conversion Recent Onset Atrial Fibrillation (AF)

Study · id `cardio:ct-nct04680026` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04680026](<https://clinicaltrials.gov/study/NCT04680026>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04680026

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 150 participants.

## Technical summary

Registry record NCT04680026. Randomized; quadruple masking; primary purpose treatment. Start 2021-06-01 (actual); primary completion 2025-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 150 participants (planned count; ClinicalTrials.gov record NCT04680026, source copy `cardio:ctgov-nct04680026-2025-12-02`, retrieved 2026-10-26)
- Started: 2021-06-01 (actual) (ClinicalTrials.gov record NCT04680026, source copy `cardio:ctgov-nct04680026-2025-12-02`, retrieved 2026-10-26)
- Primary completion: 2025-12-31 (anticipated) (ClinicalTrials.gov record NCT04680026, source copy `cardio:ctgov-nct04680026-2025-12-02`, retrieved 2026-10-26)
- Completion: 2025-12-31 (anticipated) (ClinicalTrials.gov record NCT04680026, source copy `cardio:ctgov-nct04680026-2025-12-02`, retrieved 2026-10-26)
- Countries: United States; Bosnia & Herzegovina; Canada; New Zealand; Serbia (ClinicalTrials.gov record NCT04680026, source copy `cardio:ctgov-nct04680026-2025-12-02`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04680026-2025-12-02`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of IV HBI-3000 for the Conversion Recent Onset Atrial Fibrillation (AF)
- Condition: Atrial Fibrillation
- Intervention (Drug): HBI-3000
- Intervention (Drug): Placebo
- Lead sponsor: HUYABIO International, LLC.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)

## Provenance

Content hash: d9e769c0930c3566acb0c70a3cc33b6a3ef819f9af044d75a3714c78e21ec293
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
